New Frontier Pharmaceuticals (06108.HK) released its interim performance, with a net loss of HKD 7.454 million, an 82.3% increase compared to the same period last year.

According to the WiseFinance app, New Prosperity Pharmaceuticals (06108.HK) released its mid-term performance for 2025, with revenue of 44.701 million Hong Kong dollars, a year-on-year increase of 167.4%; a net loss of 7.454 million Hong Kong dollars, a year-on-year increase of 82.3%; and a basic loss per share of 0.45 Hong Kong cents.